Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Clinics in Liver Disease
|
November 23, 2019
Drug-Induced Liver Injury Resources and Reporting for the Clinician
Marisa Isaacson, Michael Babich
Oncotargets and Therapy
|
December 7, 2019
Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer
James A Radosevich, Michael Babich
Advances in Virology
|
August 2, 2012
Hepatitis C variability, patterns of resistance, and impact on therapy
Cristina Simona Strahotin, Michael Babich
Clinics in Liver Disease
|
November 28, 2024
The Role of Palliative Care in the Management of Patients with Hepatocellular Carcinoma
Nabeeha Mohy-Ud-Din, Michael Babich
Case Reports in Gastroenterology
|
July 13, 2016
Idiopathic Adulthood Ductopenia: 'It Is Out There'
Mohammad Bilal, Ali Kazemi, Michael Babich
Drugs of Today (Barcelona, Spain : 1998)
|
May 14, 2009
Fundamentals of antibody-related therapy and diagnostics
Huguette Albrecht, James A Radosevich, Michael Babich
BMJ Case Reports
|
January 29, 2015
Intense pruritus in Epstein-Barr virus (EBV) hepatitis treated with naloxone drip
Satyanisth Agrawal, Ryan O'Connor, Elie Aoun, et al.
Case Reports in Hepatology
|
August 5, 2015
Linoleic Acid Induced Acute Hepatitis: A Case Report and Review of the Literature
Mohammad Bilal, Yogesh Patel, Micheal Burkitt, et al.
Digestive Diseases and Sciences
|
February 24, 2021
Gastroenterology Fellowship Applicants' Perspectives on GI Program Preferences
Usman Tariq, Shifa Umar, Suzanne Morrissey, et al.
Heliyon
|
March 7, 2022
Labyrinthin: A distinct pan-adenocarcinoma diagnostic and immunotherapeutic tumor specific antigen
Michael Babich, Ankit Sharma, Tianhong Li, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Clinics in Liver Disease
|
November 23, 2019
Drug-Induced Liver Injury Resources and Reporting for the Clinician
Marisa Isaacson, Michael Babich
Oncotargets and Therapy
|
December 7, 2019
Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer
James A Radosevich, Michael Babich
Advances in Virology
|
August 2, 2012
Hepatitis C variability, patterns of resistance, and impact on therapy
Cristina Simona Strahotin, Michael Babich
Clinics in Liver Disease
|
November 28, 2024
The Role of Palliative Care in the Management of Patients with Hepatocellular Carcinoma
Nabeeha Mohy-Ud-Din, Michael Babich
Case Reports in Gastroenterology
|
July 13, 2016
Idiopathic Adulthood Ductopenia: 'It Is Out There'
Mohammad Bilal, Ali Kazemi, Michael Babich
Drugs of Today (Barcelona, Spain : 1998)
|
May 14, 2009
Fundamentals of antibody-related therapy and diagnostics
Huguette Albrecht, James A Radosevich, Michael Babich
BMJ Case Reports
|
January 29, 2015
Intense pruritus in Epstein-Barr virus (EBV) hepatitis treated with naloxone drip
Satyanisth Agrawal, Ryan O'Connor, Elie Aoun, et al.
Case Reports in Hepatology
|
August 5, 2015
Linoleic Acid Induced Acute Hepatitis: A Case Report and Review of the Literature
Mohammad Bilal, Yogesh Patel, Micheal Burkitt, et al.
Digestive Diseases and Sciences
|
February 24, 2021
Gastroenterology Fellowship Applicants' Perspectives on GI Program Preferences
Usman Tariq, Shifa Umar, Suzanne Morrissey, et al.
Heliyon
|
March 7, 2022
Labyrinthin: A distinct pan-adenocarcinoma diagnostic and immunotherapeutic tumor specific antigen
Michael Babich, Ankit Sharma, Tianhong Li, et al.
Page
of 2